Advaxis, Inc. ADXS · Stock Open Advaxis, Inc. in new tab
Advaxis, Inc. Analysis (ADXS)
Is Advaxis, Inc. a good investment? Advaxis, Inc. (ADXS) is currently trading at 0.6036 USD.
Investor FAQ
Does Advaxis, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Advaxis, Inc.?
Advaxis, Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.
Company Profile
Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc.; OS Therapies, LLC; Aratana Therapeutics Inc.; Biocon Limited; Global BioPharma Inc.; Knight Therapeutics Inc; and others. Advaxis, Inc. was founded in 2002 and is based in Monmouth Junction, New Jersey.
Community Discussion